A 2012 editorial published by senior regulators from the European Medicines agency[REF] largely agreed with AllTrials, saying "We consider it neither desirable nor realistic to maintain the status quo of limited availability of regulatory trials data".
They suggested that reanalyses should therefore be subject to the same regulations as sponsor analyses, such as registering analysis plans.